Suppr超能文献

重新审视流感嗜血杆菌对氨苄西林和头孢噻肟的突变耐药性。

Revisiting mutational resistance to ampicillin and cefotaxime in Haemophilus influenzae.

作者信息

Diricks Margo, Petersen Sabine, Bartels Lennart, Lâm Thiên-Trí, Claus Heike, Bajanca-Lavado Maria Paula, Hauswaldt Susanne, Stolze Ricardo, Vázquez Omar Jiménez, Utpatel Christian, Niemann Stefan, Rupp Jan, Wohlers Inken, Merker Matthias

机构信息

Molecular and Experimental Mycobacteriology, Research Center Borstel, Borstel, Germany.

German Center for Infection Research, Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel-Lübeck, Germany.

出版信息

Genome Med. 2024 Dec 4;16(1):140. doi: 10.1186/s13073-024-01406-4.

Abstract

BACKGROUND

Haemophilus influenzae is an opportunistic bacterial pathogen that can cause severe respiratory tract and invasive infections. The emergence of β-lactamase-negative ampicillin-resistant (BLNAR) strains and unclear correlations between genotypic (i.e., gBLNAR) and phenotypic resistance are challenging empirical treatments and patient management. Thus, we sought to revisit molecular resistance mechanisms and to identify new resistance determinants of H. influenzae.

METHODS

We performed a systematic meta-analysis of H. influenzae isolates (n = 291) to quantify the association of phenotypic ampicillin and cefotaxime resistance with previously defined resistance groups, i.e., specific substitution patterns of the penicillin binding protein PBP3, encoded by ftsI. Using phylogenomics and a genome-wide association study (GWAS), we investigated evolutionary trajectories and novel resistance determinants in a public global cohort (n = 555) and a new clinical cohort from three European centers (n = 298), respectively.

RESULTS

Our meta-analysis confirmed that PBP3 group II- and group III-related isolates were significantly associated with phenotypic resistance to ampicillin (p < 0.001), while only group III-related isolates were associated with resistance to cefotaxime (p = 0.02). The vast majority of H. influenzae isolates not classified into a PBP3 resistance group were ampicillin and cefotaxime susceptible. However, particularly group II isolates had low specificities (< 16%) to rule in ampicillin resistance due to clinical breakpoints classifying many of them as phenotypically susceptible. We found indications for positive selection of multiple PBP3 substitutions, which evolved independently and often step-wise in different phylogenetic clades. Beyond ftsI, other possible candidate genes (e.g., oppA, ridA, and ompP2) were moderately associated with ampicillin resistance in the GWAS. The PBP3 substitutions M377I, A502V, N526K, V547I, and N569S were most strongly related to ampicillin resistance and occurred in combination in the most prevalent resistant haplotype H1 in our clinical cohort.

CONCLUSIONS

Gradient agar diffusion strips and broth microdilution assays do not consistently classify isolates from PBP3 groups as phenotypically resistant. Consequently, when the minimum inhibitory concentration is close to the clinical breakpoints, and genotypic data is available, PBP3 resistance groups should be prioritized over susceptible phenotypic results for ampicillin. The implications on treatment outcome and bacterial fitness of other extended PBP3 substitution patterns and novel candidate genes need to be determined.

摘要

背景

流感嗜血杆菌是一种机会性细菌病原体,可引起严重的呼吸道感染和侵袭性感染。β-内酰胺酶阴性氨苄西林耐药(BLNAR)菌株的出现以及基因型(即gBLNAR)与表型耐药之间不明确的相关性,对经验性治疗和患者管理构成了挑战。因此,我们试图重新审视分子耐药机制,并确定流感嗜血杆菌的新耐药决定因素。

方法

我们对流感嗜血杆菌分离株(n = 291)进行了系统的荟萃分析,以量化表型氨苄西林和头孢噻肟耐药与先前定义的耐药组之间的关联,即由ftsI编码的青霉素结合蛋白PBP3的特定替代模式。我们分别使用系统发育基因组学和全基因组关联研究(GWAS),在一个全球公共队列(n = 555)和来自三个欧洲中心的一个新临床队列(n = 298)中研究进化轨迹和新的耐药决定因素。

结果

我们的荟萃分析证实,PBP3 II组和III组相关分离株与氨苄西林表型耐药显著相关(p < 0.001),而只有III组相关分离株与头孢噻肟耐药相关(p = 0.02)。绝大多数未分类到PBP3耐药组的流感嗜血杆菌分离株对氨苄西林和头孢噻肟敏感。然而,特别是II组分离株在判定氨苄西林耐药方面的特异性较低(< 16%),因为临床断点将其中许多分离株分类为表型敏感。我们发现了多个PBP3替代的正选择迹象,这些替代在不同的系统发育分支中独立且通常逐步进化。除ftsI外,其他可能的候选基因(如oppA、ridA和ompP2)在GWAS中与氨苄西林耐药呈中度相关。PBP3替代M377I、A502V、N526K、V547I和N569S与氨苄西林耐药关系最为密切,并在我们临床队列中最常见的耐药单倍型H1中组合出现。

结论

梯度琼脂扩散条和肉汤微量稀释试验不能始终如一地将来自PBP3组的分离株分类为表型耐药。因此,当最低抑菌浓度接近临床断点且有基因型数据时,对于氨苄西林,应优先考虑PBP3耐药组而非敏感的表型结果。其他扩展的PBP3替代模式和新候选基因对治疗结果和细菌适应性的影响需要确定。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b66b/11616347/00c5d132fc94/13073_2024_1406_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验